What changed
$MDB — AVOID 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ1 FY2027 (ends Apr) | reported May 28 | Rev $688M | EPS $-0.45 vs $-0.30 🔴 | Margin -3.6%
💡 Consensus expects sustained 25%+ growth and eventual margin expansion, but the large miss on bottom line and high SBC suggest estimates may be too high, while the stock is priced for perfection.
🏢 Business Quality: 6/10
📊 Valuation: rich
🔮 Catalyst: Next quarterly earnings
⚖️ Avoid MDB long at $314; rich multiples and no near-term catalyst make risk/reward unfavorable; consider on a pullback below $250.